Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to share significant news regarding the company's decision to terminate its previously announced letter agreement with VCI Global Limited to sell up to a 51% interest in the company's artificial intelligence platform for 3D modeling and associated assets.

Gappelberg explained that the company made the decision to terminate the agreement because VCI Global Limited was unable to meet its conditions precedent within the mutually agreed timelines. As a result, Nextech3D.ai has no plans to sell its 3D modeling business. Instead, the company intends to continue building its AI technology stack to scale 3D modeling while retaining ownership, operation, and development of the business.

The company sees substantial growth potential through partnerships with Amazon and other large enterprise clients, which it believes will provide significant growth opportunities. This strategic decision allows Nextech3D.ai to maintain control over its AI technology and 3D modeling business, positioning it for continued growth and innovation in the industry.

#proactiveinvestors #nextech3d.ai #cse #NTAR #otcqb #metaverse #toggle3D

#3DModeling #TechNews #EcommerceTech #AmazonPartnership #BusinessGrowth #DigitalInnovation #CEOInsights #TechIndustry #EnterpriseDeals #InvestmentUpdate #EmergingTech #FutureTech #DigitalTransformation #EvanGappelberg #VRTechnology #AugmentedReality #DigitalCommerce #InnovationLeadership #TechInnovations #IndustryUpdates #DigitalMarketing #AIIntegration #StrategicPartnerships #AmazonSellerCentral

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

OptionsDesk's Sebastian Blanco previews a busy week on the markets for US corporate earnings and interest-rate decisions.

With five of the "Magnificent Seven" reporting quarterly earnings this week, Blanco highlighted the shift from CPU to GPU chip makers, driven by AI industry demands, noting AMD and Nvidia's emerging leadership. He pointed out Intel's significant revenue forecast miss and Tesla's earnings shortfall last week led to substantial market value losses for both.

Microsoft's recent overtaking of Apple as the world's most valuable company was a significant focus. Blanco attributed Microsoft's success to its dominance in the AI sector, contrasting with Apple's challenges, including softer demand in China and a need to detail its AI strategy. He suggested that Apple's earnings, due on Thursday, would be crucial, especially considering Microsoft's stock surge and Apple's relatively flat performance.

Blanco also shared trading insights, emphasizing the potential of a 'strangle' strategy and the benefits of diversified tech-focused exchange-traded funds (ETFs) in portfolios. He recommended considering ETFs that cover the broader tech sector or those focused on major tech firms, citing the shift towards GPU-focused chipmakers.

‌

#SebastianBlanco #Optionsdesk #TechSector #USearnings #InterestRates #USMarket #UKMarket #TechEarnings #CPUGPUSwitch #AMD #Nvidia #Intel #Tesla #Microsoft #Apple #AIIndustry #StockMarket #TradingStrategies #ETFs #FinancialAnalysis #MarketInsights #Investing #FinanceNews #EconomicTrends #PriceOfLondon #CorporateResults #TechStocks #InvestmentIdeas #FinancialExpert #MarketForecast #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Newmark Security PLC CEO Marie-Claire Dwek takes Proactive's Stephen Gunnion through the company's first-half performance, which revealed strong underlying growth.

The company, which designs and manufactures physical security products, intelligent access control, timekeeping and identity management solutions, reported first-half revenues of £10.4 million and a gross profit of £3.9 million, marking an 11% increase after adjusting for the departure of UKG, a former client.

Notably, EBITDA soared to £5.8 million. The addition of three major clients in the first quarter contributed significantly to revenue. Additionally, Newmark Security has been actively expanding its service offerings, resulting in a notable increase in recurring revenue in HCM, totaling £2.3 million for the year.

Dwek expressed optimism about returning to profit after tax in the second quarter, anticipating a strong second half of the year bolstered by new clients and strategies. The company's focus on attracting more blue-chip customers across various sectors, including software houses in the US and major UK retailers, has been fruitful. Newmark Security's access control division has also seen success with blue-chip clients in the UK through distributors and dealers.

Looking ahead, the sales pipeline remains strong for the second half of the year. Newmark Security's strategic plan, which includes attaching services to hardware and introducing new products to existing partners, is proving successful.

‌

#NewmarkSecurity #MarieClaireDwek #SecurityIndustry #FinancialResults2024 #HCMTimeandAttendance #USMarketExpansion #GrossProfitGrowth #BlueChipClients #RetailSector #AccessControl #EBITDAIncrease #RevenueGrowth #ProactiveInterview #TechInnovation #BusinessStrategy #CorporateGrowth #UKRetailers #SoftwareHouses #ProfitReturn2024 #StrategicPlanning #BusinessInterview #CEOInsights

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Faron Pharmaceuticals Ltd chief executive Dr Markku Jalkanen joined Proactive's Stephen Gunnion with encouraging outcomes from latest cancer treatment trials.

The pharmaceutical company has observed a significant response rate in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Remarkably, within the MDS group, the response rate hit 100%.

These results come from the company's research combining immunotherapy and chemotherapy.

This combination has shown effectiveness even in patients who were previously refractory to standard treatments, including BCL-2 inhibitors, macro Lima, and sundry map. The treatment aims to eradicate cancer cells, leading to complete remission and has demonstrated a profound change in patient profiles.

Dr Jalkanen highlighted that this is part of the second phase of the ongoing 'next map' trial, which involves a careful dose escalation process under FDA guidelines. The trial aims to finalize dosing levels this year, moving towards pivotal phases and regulatory approval.

With a response rate anticipated to be significantly higher than current treatments, the company is eyeing a potential breakthrough in treating aggressive myeloid malignancies, which have short life expectancies.

The company plans to submit additional data from 32 patients to determine the final dose levels, leading to a decisive pivotal trial. With hopes of gaining FDA approval, Faron Pharmaceuticals is positioned to make a substantial impact on cancer treatment, potentially bringing new hope to patients with limited options.

‌

#FaronPharmaceuticals #CancerResearch #Immunotherapy #Chemotherapy #AcuteMyeloidLeukemia #MyelodysplasticSyndromes #ClinicalTrials #MedicalInnovation #FDAApproval #HealthcareNews #Oncology #CancerTreatment #PharmaceuticalIndustry #MedicalBreakthrough #MarkkuJalkanen #CancerTherapy #AML #MDS #NextMapTrial #PharmaNews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Chariot Ltd (AIM:CHAR, OTC:OIGLF) chief executive Adonis Pouroulis says the company is poised for a significant year in 2024, focusing on transitional energy and green initiatives.

In an interview with Proactive's Stephen Gunnion, Pouroulis highlighted key developments across Chariot's diverse portfolio, emphasizing its strategic progress in various sectors.

The primary focus is on Chariot's transitional gas assets, especially in Morocco. The company is set to drill two wells in the Loukos license, with preparations well underway. This move is complemented by a partnership with Energean for offshore Moroccan projects, awaiting regulatory approval. These collaborations aim to expand existing developments and drill a multi-objective appraisal later in the year.

Chariot's trading business in South Africa is addressing the acute energy shortage in the country. The company recently increased its stake to 49% in this venture, foreseeing a significant growth opportunity in one of the world's largest markets undergoing major deregulation.

Renewable projects for mining operations are advancing, with more updates expected. Furthermore, Chariot's green hydrogen pillar is making strides with Project Nour, in partnership with Total Energies in Mauritania. The completed feasibility study will soon be presented to the Mauritanian government.

Despite a recent dip in share price, Pouroulis remains confident in Chariot's solid fundamentals and upcoming catalysts in 2024. The management's significant share ownership and recent purchases by directors affirm their commitment to the company's success.

#ChariotLtd #AdonisPouroulis #EnergySector #TransitionalGas #RenewableEnergy #GreenHydrogen #MoroccoEnergy #EnergeanPartnership #SouthAfricaEnergy #ProjectNora #TotalEnergies #Mauritania #GreenElectricity #EnergyShortage #MiningOperations #EnergyMarket #ShareholderValue #OilAndGasIndustry #EnergyInvestment #CEOInterview #ProactiveLondon #EnergyUpdates2024 #TransitionalEnergy #EnergyInnovation #EnergyStrategy #SustainableEnergy #EnergyDevelopment #GlobalEnergy #EnergyTransition #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Blencowe Resources PLC CEO Mike Ralston joined Proactive's Stephen Gunnion with an update on the company's Orem-Cross Graphite Project after the company received a formal Letter of Interest (LOI) from the US International Development Finance Corporation (DFC) stating the agency is willing to take part in the debt funding for the project.

Ralston told Proactive the project has evolved through various stages, including drilling, scoping studies, and a pre-feasibility study, which indicated an impressive net present value (NPV). Currently, it is in the definitive feasibility study stage. Ralston highlighted graphite's growing importance, especially in lithium-ion batteries, underscoring the high value of the project.

Ralston also elaborated on Blencowe's partnership with DFC. This collaboration began last year with a $5 million grant for feasibility study costs, of which $2 million has already been received. The DFC, committed to funding green projects, aligns with Blencowe's objectives, including critical minerals supply chain development. This partnership is crucial for Blencowe, as DFC will be the lead provider for funding the full project implementation.

Ralston also addressed the EV market and graphite's role in it. While noting a slowdown in the Chinese EV market, he remains optimistic about the overall growth in EVs and lithium-ion batteries. Ralston emphasized graphite's diverse applications beyond EVs and expressed confidence in the Orem-Cross project's potential, given its low capital and operating costs and high-quality product.

#BlencoweResources #MikeRalston #GraphiteMining #OremCrossProject #LithiumIonBatteries #MiningIndustry #ResourceDevelopment #DevelopmentFinanceCorporation #InvestmentInMining #GreenProjects #CriticalMinerals #GraphiteMarket #EVMarket #SustainableMining #LondonStockExchange #BRES #NaturalResources #RenewableEnergy #BatteryMetals #MineralExploration #FeasibilityStudy #CorporateInterview #ProactiveLondon #Finance #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive Research Analyst John Savin discusses NanoViricides' significant progress in a new report.

The company has successfully completed dosing in a Phase 1a COVID study, marking a major milestone for any biotech firm. The key takeaway is the safety of the dosing, even at the highest levels, in healthy participants.

NanoViricides plans to advance to a Phase 1b study with actual COVID patients in India, where a surge in cases provides an opportune environment for clinical trials. This study focuses on a highly transmissible but not more dangerous COVID variant.

Savin highlights the company's broader ambitions to conduct trials for other viruses, demonstrating its versatile research capabilities. The financial aspect is also promising; NanoViricides reported having about $7 million in cash for the half-year, with an additional over $2 million loan from the CEO, ensuring adequate funding for ongoing programs.

The discussion also touched on the potential for US trials. The current studies are precursors to US trials, which are crucial for maximizing commercial potential. The FDA's interest in reviewing these studies was noted, although it remains uncertain whether a new Phase 1 will be required in the US or if it will directly proceed to Phase 2.

https://www.proactiveinvestors.co.uk/companies/news/1039564/nanoviricides-phase-ia-b-healthy-participant-dosing-completed-pox-virus-data-1039564.html/long

‌

#NanoViricides #JohnSavin #ProactiveResearch #Biotech #COVID19Research #Phase1Study #ClinicalTrials #VirusResearch #HealthcareInnovation #MedicalScience #Pharmaceuticals #COVID19Treatment #HealthSector #Biotechnology #ClinicalDevelopment #DrugDevelopment #InvestmentInsights #HealthcareIndustry #FDARegulations #COVIDVariants #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Golden Metal Resources PLC chief executive Oliver Friesen shares key insights about his company's strategic focus and future outlook in an interview with Proactive London.

Golden Metal Resources, listed on the AIM market in London under the ticker GMET, is primarily concentrated on exploration and development in Nevada, recognized as a top mining jurisdiction globally. Its flagship project, Pilot Mountain, is particularly notable for hosting the largest undeveloped tungsten deposit in the US, a significant point amid rising geopolitical tensions and the critical need for diverse metal supply chains.

Friesen emphasized tungsten's growing importance, highlighting its extensive use in the military and emerging applications in nuclear fusion technology. With China dominating about 86% of the global tungsten supply, Golden Metal Resources aims to diversify this reliance, leveraging its US-based assets. Additionally, the company is tapping into the burgeoning demand for copper, vital for green technologies and global electrification efforts. Its Garfield property shows promise as a significant copper Porphyry, complementing its tungsten focus.

Pilot Mountain is currently at the resource development stage, and the company is in discussions for non-dilutive government grant funding due to the project's strategic importance.

Friesen expressed optimism for 2024, citing a general underinvestment in the junior metals and mining sector and an increasing demand for metals like tungsten and copper. He believes Golden Metal Resources is well-positioned to capitalize on these trends, especially with supportive government policies and funding in the US.

‌

#GoldenMetalResources #OliverFriesen #MiningIndustry #TungstenMining #CopperMining #NevadaMining #AIMMarket #PilotMountainProject #GreenTechnology #MetalsAndMining #ResourceDevelopment #MiningExploration #USMiningSector #CommodityTrends #JuniorMiningSector #GlobalMetalSupply #DefenseMetals #NuclearFusion #MiningInvestment #2024MiningOutlook #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive's William "Billy" Farrington, gives key insights into the current cryptocurrency market, particularly Bitcoin.

Bitcoin experienced a sluggish week, dipping below $39,000 for the first time in a while, but saw a notable 3% rally against the US dollar, pushing it above $41,000. Farrington attributes this to positive US economic data and a consequent dip in the dollar index, fostering a favorable environment for Bitcoin.

A significant focus was the recent approval of Bitcoin-linked ETFs in the US. Despite high expectations, Bitcoin's value dipped post-approval, a phenomenon Farrington describes as a "sell the news" situation, where the hype was already factored into Bitcoin's price. However, ETFs have seen substantial activity, with total inflows reaching $824 million and trading volumes surpassing $21 billion.

Farrington also highlighted the outflows from the Grayscale Bitcoin Trust (GBTC), the largest of these ETFs. He explained that the high management fees of GBTC, at 1.5% yearly, are driving investors towards more cost-effective options. Despite Grayscale's claims of high liquidity and low spreads, the market currently favours lower-cost alternatives.

Looking ahead, Farrington suggests monitoring the balance of inflows and outflows in these ETFs, as this could significantly impact Bitcoin's price. He remains cautious, noting that the market is still in a "sell the news" phase, but acknowledges the potential for positive momentum in the future. This interview provides valuable insights for those interested in cryptocurrency trends and the effects of macroeconomic factors on Bitcoin's value.

‌

#Cryptocurrency #Bitcoin #CryptoMarket #CryptoNews #BitcoinETF #BitcoinAnalysis #CryptoTrading #DigitalCurrency #Blockchain #Investment #Finance #EconomicData #MarketTrends #BitcoinPrice #TradingVolume #ETFTrading #CryptoInsights #MarketAnalysis #BitcoinUpdate #Proactive #WilliamFarrington #CryptoJournalism #CryptoRoundup #Investing #FinancialNews #EconomicTrends #CryptoEconomy #BitcoinOutlook #FinancialMarkets #CryptoStrategy #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

BB Biotech AG head portfolio manager Dr Daniel Koller outlines the company's investment strategy and performance in an interview with Proactive London.

BB Biotech, a Swiss investment firm with a 30-year track record, focuses on constructing a concentrated portfolio of 20-35 biotechnology stocks. The company aims for double-digit returns, targeting a 15% return on invested capital over a cycle.

Koller detailed the firm's "S curve" investment strategy, which involves identifying companies at the proof of concept stage, primarily in the small to mid-cap range, and investing in them for the medium to long term. This approach allows BB Biotech to support companies through their growth phases, from clinical to commercial stages, and divest when growth slows or targets are no longer achievable.

The fund focuses on therapeutic areas like cancer, autoimmune diseases, and rare genetic disorders. It also pays close attention to evolving technologies in drug development, including RNA medicines, gene therapies, and cell-based treatments.

Koller also highlighted the integration of artificial intelligence in their operations, employing data scientists to enhance due diligence and identify optimal investment opportunities in a field that has grown from a few hundred to thousands of companies.

Despite recent market challenges, Koller remains optimistic about the fund's performance. He acknowledges a downturn in the biotech sector over the last two years but points to the substantial progress made by portfolio companies. He cites factors such as changing interest rate environments, increased mergers and acquisitions, and clinical advancements as drivers for a positive turnaround in the fourth quarter and early 2024.

#BBBiotech #InvestmentStrategy #Biotechnology #PortfolioManagement #StockMarket #SwissInvestmentFirm #DanielKoller #ProactiveLondon #FundManagement #BiotechInvesting #HealthcareInvestments #ScurveStrategy #TherapeuticInvestment #ArtificialIntelligenceInInvesting #FinancialMarkets #BiotechSector #MarketPerformance #InvestmentTrends #ClinicalStageInvesting #CommercialStageInvesting #BiotechStocks #InvestmentInsights #FinancialAnalysis #StockPortfolio #InvestorEducation #MarketInsights #FinanceInterview #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews